Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Part of paid clinical trials in Stanford, California.
- Sponsor
- Stanford University
- Study ID
- NCT01019148
- Status
- Recruiting
Conditions
- Epidermolysis Bullosa Dystrophica
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Key Dates
- Start date
- Nov 10, 2009
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 70 participants (estimated)
Primary Outcome Measure
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa [ Time Frame: 10 years ]
Central Contacts
- Irene Bailey-Healy(650) 721-7149
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | Jean Tang, MD, PhD (PRINCIPAL_INVESTIGATOR) M. Peter Marinkovich, MD (SUB_INVESTIGATOR) Anthony Oro, MD (SUB_INVESTIGATOR) |
Find similar trials in Stanford, CA
By research site
Related Studies
- A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)Recruiting · Krystal Biotech, Inc. · Pittsburgh, Pennsylvania